Search
for
Sort by
Research 30 of 248
- SAT340 Matters Of The HAART - Ritonavir Induced CYP3A4 Inhibition of Intranasal Fluticasone Leading To Cushing’s Syndrome
- Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Drug safety evaluation of exemestane
- Effect of a Benign Prostatic Hyperplasia (BPH) Xenobiotic - Croton membranaceus Müll.Arg. Root Extract on CYP1A2, CYP3A4, CYP2D6, and GSTM1 Drug Metabolizing Enzymes in Rat Model
- Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency Due to an Interaction Between Fluticasone and Ritonavir
- Arecaceae
- Docking-based workflow and ADME prediction of some compounds in Curcuma longa and Andrographis paniculata as polymerase PA-PB1 inhibitors of influenza A/H5N1 virus
- Effects of mitotane treatment on human steroid metabolism: implications for patient management
- Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – active Phytochemicals and In Vivo Molecular Targets
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Analysis of metabolic characteristics of epristeride in zebrafish based on LC-Q-TOF MS and its potential applications in doping control
- Ritlecitinib: First Approval
- The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
- Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: Endocrine system and lipid metabolism disruption
- Endocrine effects of long-term calcineurin inhibitor use in solid organ transplant recipients
- Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient
- Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- Anti-Aging, Anti-Inflammatory, and Cytoprotective Properties of Lactobacillus- and Kombucha-Fermented C. pepo L. Peel and Pulp Extracts with Prototype Skin Toner Development
- Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Ruxolitinib Rescues Multiorgan Clinical Autoimmunity in Patients with APS-1
- Therapeutic potential of <i>Asiaticoside</i> in wound healing after endoscopic submucosal dissection (ESD)